期刊文献+

重组质粒pZeoSV2(+)/CpG-HBcAg(ISS)对Balb/c小鼠的免疫作用 被引量:1

Immune effects of recombinant plasmid pZeoSV2(+)/CpG-HBcAg(ISS) action on Balb/c mouse
下载PDF
导出
摘要 目的探讨重组质粒pZeoSV2(+)/CpG-HBcAg(ISS)对Balb/c小鼠免疫的作用。方法构建真核表达质粒pZeoSV2(+)/CpG-HBcAg(ISSb,ISSc),将其免疫Balb/c小鼠,ELISA法检测免疫后小鼠血清中HBcAb、IFN-γ、IL-2、IL-12、IL-4和IL-10的含量。结果 pZeoSV2(+)/CpG-HBcAg(ISSb,ISSc)重组质粒均能诱导Balb/c小鼠产生特异性抗体HBcAb,pZeoSV2(+)/CpG-HBcAg(ISSb)组较pZeoSV2(+)/CpG-HBcAg(ISSc)组产生的抗-HBc效价显著增高(P<0.01),且其免疫Balb/c小鼠后能使Th1型细胞因子IFN-γ、IL-2和IL-12的表达增强,抑制Th2型细胞因子IL-4和IL-10的产生。结论 pZeoSV2(+)/CpG-HBcAg(ISSb,ISSc)重组质粒对小鼠HBcAb的产生具有明显的促进作用,含CpG-HBcAg(ISSb)的重组质粒能够明显增强小鼠血清Th1型细胞因子的表达,抑制Th2型细胞因子的表达。 CpG motif can induce strong Thl response, which is necessary for chronic hepatitis B in the study, thus we explore the immune effects of recombinant plasmids pZeoSV2 (+)/CpG-HBcAg (ISS) on of Balb/c mice. Recombinant plasmid pZeoSV2 (+)/CpG-HBcAg (ISSb, ISSc) was used to immune Balb/c mice, then the serum HBcAb, IFN-γ IL-2, IL-12, IL-4, and IL-10 levels were detected by ELISA. The pZeoSV2 (+)/CpG-HBcAg (ISSb, ISSc) recombinant plasmids could induce HBcAb production in Balb/c mice. Furthermore, anti-HBc titers of pZeoSV2(+)/CpG-HBcAg (ISSb) group were obviously higher than that of pZeoSV2 (+)/CpG-HBcAg (ISSc) group (P 〈 0.01). The result showed that high levels of Thl type cytokines including IL-2, IFN-γ and IL-12 were be induced in pZeoSV2 (+)/CpG- HBcAg (ISSb) recombinant plasmid groups, while the levels of Th2 type cytokines such as IL-4 and IL-10 were inhibited obviously. All the results suggest that pZeoSV2(+)/CpG-HBcAg (ISSb, c) recombinant plasmid plays a crucial role on HBcAb production in Balb/c mice, and could induce the expression of Thl type cytokines, whereas inhibited the expression of Th2 type cytokines.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第3期211-214,219,共5页 Immunological Journal
基金 湖北省自然科学基金资助项目(2006ABA139)
关键词 CPG基序 乙肝核心抗原 树突状细胞 共刺激分子 TH1/TH2型细胞因子 CpG motif HBcAg Dendritic cells Co-stimulary molecule Th1/Th2 type cytokine
  • 相关文献

参考文献13

  • 1Lowrie DB, Whalen RG. DNA vaccine: methods and protocols [M]. New Jersey: Humana Press, 1999:169.
  • 2Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receplor recognizes bacterial DNA [J]. Nature, 2000, 408 (6813): 740-745.
  • 3Takeshita F, Leifer CA, Gursel I, el al. Cutting edge: role of Toll-like receptor 9 in CpG DNA induced activation of human cells[J].J Immunol, 2001, 167 (7): 3555-3558.
  • 4Li Jun, Fu Ning. Progress in the research of TLR9 [J]. Immunol J, 2004, 20 (3): 73-75.
  • 5张政,王福生.CpG-ODN免疫学功能及其应用研究[J].免疫学杂志,2003,19(S1):122-125. 被引量:11
  • 6Messina JP, Gilkeson GS, Pisetsky DS, et al. Stimulation of in vitro routine lymphocyte proliferation by bacterial DNA [J]. J Immunol, 1991, 147(6): 1759-1764.
  • 7Stacey K J, Sweet M J, Hume DA, et al. Macrophages ingest and are activated by bacterial DNA [J]. J Immunol, 1996, 157 (5): 2116-2122.
  • 8Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonueleotides trigger maturation and activation of murine dendritic cells [J]. Eur J Immunol, 1998, 28 (6): 2045-2054.
  • 9Rosa DS, Bastos KR, Bargieri DY, et al. Role of interferon gamma during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins [J]. Vaccine, 2007, 25 (32): 6007-6017.
  • 10Cebrat M, Cebula A, Laszkiewicz A, et al. Mechanism of Lymphocyte-specific inactivation of RAG-2 intragenic promoter of NWC: Implications for epigenetic control of RAG locus[J]. Mol Immunol, 2008, 45 (8): 2297-2306.

二级参考文献25

  • 1李宁,范学工,黄燕,刘征波,全俊,汤参娥,朱才.CpG-ODN对慢性乙型肝炎患者外周血单个核细胞T-bet表达的影响[J].免疫学杂志,2005,21(3):216-218. 被引量:5
  • 2李宁,范学工,陈立章,陈朝晖,刘洪波.CpG-ODN活化人NK细胞的初步研究[J].中国免疫学杂志,2005,21(6):424-426. 被引量:3
  • 3Krig AM.CpG motifs in bacterial DNA and their immune effects[J].Annu Rev Immunol,2002,20:709-760.
  • 4Klinman DM.Immunotherapeutic uses of CpG oligodeoxynucleotides[J].Nat Immuol,2004,4(1):1-10.
  • 5Harandi AM,Eriksson K,Holmgren J.A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection[ J].J Virol,2003,77(2):953-962.
  • 6Ashkar AA,Bauer S,Mitchell WJ,et al.Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication,but not entry,of herpes simplex virus type 2[J].J Virol,2003,77(16):8948-8956.
  • 7Siegal FP,Kadowaki N,Shodell M,et al.The nature of the principal type Ⅰ interferon-producing cells in human blood[J].Science,1999,284(5421):1835-1837.
  • 8Molen RG,Sprengers D,Binds RS,et al.Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
  • 9Krug A,Rothenfusser S,Hornung V,et al.Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells[J].Eur J Immunol,2001,31(7):2154-2163.
  • 10Kemp TJ,Elzey BD,Griffith TS,et al.Plasmacytoid dendritic cell-derived IFN-α induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide simulation[J].J Immunol,2003,171 (1):212-218.

共引文献12

同被引文献10

  • 1张政,王福生.CpG-ODN免疫学功能及其应用研究[J].免疫学杂志,2003,19(S1):122-125. 被引量:11
  • 2王甦,陈群,王兴,张燕,马丽,汪中强.乙肝疫苗联合含CpG基序寡脱氧核苷酸和卡介苗对小鼠的免疫应答影响[J].世界华人消化杂志,2005,13(17):2078-2081. 被引量:1
  • 3罗满生,郑丛龙,张卓然.CpG ODN增强rHBsAg疫苗对小鼠免疫应答影响的研究[J].微生物学杂志,2006,26(3):16-19. 被引量:2
  • 4Rohit Loomba,T Jake Liang. Novel approaches to new therapies for hepatitis B virus infection [J]. International Medical Press, 2006,11 ( 1 ) : 1-15.
  • 5Autran B,Carcelain G,Conbadiere B, et al. Therapeutic vaccine for chronic infections [J]. Science, 2004,305 ( 5681 ) : 205 -208.
  • 6Lee KR, Loft JB, et al. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device [J]. Vaccine, 2005,23 (40) : 4867-4878.
  • 7Mancini-Bourgine M, Fontaine H,Brechot C, et al. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers [J]. Vaccine,2006,24 (21): 4482-4489.
  • 8Emir S, Buyukpamuk M,Akyuz C, et al. The comparison of antibody response to different hepatitis bvaccines with and without pre-S2 antigen in children with cancer [J]. Pediatr Hematol Oncol, 2002,19(4) : 227-233.
  • 9Didici B, Bosnak M, Ucmak H, et al., Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection [J]. J Gastroenterol Hepatol,2003,18 (2) : 218-222.
  • 10BoJian Zheng,MunHon Ng,et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice [J]. Vaccine, 2001, 19(30) :4219- 4225.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部